Tanawat Geeratragool

Tanawat Geeratragool

Auto-generated profile, based on publicly available information

Tanawat Geeratragool

Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
PDF file
MRManus Rugivarodom
Manus Rugivarodom
TGTanawat Geeratragool
Tanawat Geeratragool
NPNonthalee Pausawasdi
Nonthalee Pausawasdi
PCPhunchai Charatcharoenwitthaya
Phunchai Charatcharoenwitthaya
Currently, scientific interest has focused on fat accumulation outside of subcutaneous adipose tissue. As various imaging modalities are available to quantify fat accumulation in particular organs, fatty pancreas has become an important area of research over the last decade. The pancreas has an essential role in regulating glucose metabolism and insulin secretion by responding to changes in nutrients under various metabolic circumstances. Mounting evidence has revealed that fatty pancreas is linked to impaired β-cell function and affects insulin secretion with metabolic consequences of impaired glucose metabolism, type 2 diabetes, and metabolic syndrome. It has been shown that there is a connection between fatty pancreas and the presence and severity of nonalcoholic fatty liver disease (NAFLD), which has become the predominant cause of chronic liver disease worldwide. Therefore, it is necessary to better understand the pathogenic mechanisms of fat accumulation in the pancreas and its relationship with NAFLD. This review summarizes the epidemiology, diagnosis, risk factors, and metabolic consequences of fatty pancreas and discusses its pathophysiology links to NAFLD.

10 March 2023 in Viruses
Verified
Journal Article
Open access
PDF file
TGTanawat Geeratragool
Tanawat Geeratragool
PTPisit Tangkijvanich
Pisit Tangkijvanich
SNSupot Nimanong
Supot Nimanong
SCSiwaporn Chainuvati
Siwaporn Chainuvati
PCPhunchai Charatcharoenwitthaya
Phunchai Charatcharoenwitthaya
WCWatcharasak Chotiyaputta
Watcharasak Chotiyaputta
Background: International guidelines for hepatitis B infection (HBV) recommend initiating antiviral treatment based on viral replication with inflammation or fibrosis. HBV viral loads and liver fibrosis measurements are not widely available in resource-limited countries. Aim: To develop a novel scoring system for the initiation of antiviral treatment in HBV-infected patients. Methods: We examined 602 and 420 treatment-naïve, HBV mono-infected patients for derivation and validation cohorts. We performed regression analysis to identify parameters associated with the initiation of antiviral treatment based on the European Association for the Study of the Liver (EASL) guidelines. The novel score was developed based on these parameters. Results: The novel score (HePAA) was based on HBeAg (hepatitis B e-antigen), the platelet count, alanine transaminase, and albumin. The HePAA score showed excellent performance, with AUROC values of 0.926 (95% CI, 0.901–0.950) for the derivation cohort and 0.872 (95% CI, 0.833–0.910) for the validation cohort. The optimal cutoff was ≥3 points (sensitivity, 84.9%; specificity, 92.6%). The HePAA score performed better than the World Health Organization (WHO) criteria and the Risk Estimation for HCC in Chronic Hepatitis B (REACH-B) score, and it performed similarly to the Treatment Eligibility in Africa for HBV (TREAT-B) score. Conclusions: The HePAA scoring system is simple and accurate for chronic hepatitis B treatment eligibility in resource-limited countries.

31 October 2026 in Intestinal Research
Verified
Journal Article
Open access
PDF file
PWPubet Weeranawin
Pubet Weeranawin
TGTanawat Geeratragool
Tanawat Geeratragool
WKWanruchada Katchamart
Wanruchada Katchamart
JLJulajak Limsrivilai
Julajak Limsrivilai
Background/Aims: Diagnosis of intestinal tuberculosis (ITB) is challenging. Histopathology and microbiological examination remain the gold standard, but previous studies show varied diagnostic performance. We aimed to systematically evaluate the accuracy of tests to diagnose ITB in both conventional and novel methods. Methods: We searched MEDLINE and EMBASE from inception to October 2023. All studies enrolling at least 10 patients with reported information regarding the diagnosis of ITB based on endoscopic biopsy specimens, stool tests, and blood tests were included. We performed a meta-analysis using a random-effects model to estimate the performance of each test. Results: Of 3,308 abstracts reviewed, 55 studies with 6,072 participants met the inclusion criteria. Endoscopic tissue biopsy for acid-fast bacilli, the presence of caseous granuloma on histopathology, polymerase chain reaction (PCR) for tuberculosis, mycobacterial culture, and Xpert MTB/RIF showed pooled sensitivity of 12% (95% confidence interval [CI], 8%–17%), 18% (95% CI, 12%–27%), 58% (95% CI, 44%–72%), 23% (95% CI, 12%–40%) and 29% (95% CI, 17%–46%), respectively. The liquid medium culture showed higher sensitivity than conventional Lowenstein-Jensen medium (25% [95% CI, 13%–43%] and 6% [95% CI, 3%–13%]). Pooled sensitivity and specificity of stool PCR for TB were 73% (95% CI, 43%–90%) and 95% (95% CI, 79%–99%), respectively. Additionally, the pooled sensitivity and specificity of interferon-gamma release assay (IGRA) were 86% (95% CI, 79%–91%) and 86% (95% CI, 81%–89%). Conclusions: Endoscopic tissue biopsy samples had limited sensitivity in diagnosing ITB. IGRA showed good accuracy and may be combined with other methods to improve the diagnostic yield. Stool PCR demonstrated a good performance but based on a few studies.

26 September 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
NPNutchanun Preechakawin
Nutchanun Preechakawin
MMMonthira Maneerattanaporn
Monthira Maneerattanaporn
TGTanawat Geeratragool
Tanawat Geeratragool
PSPrachaya Srivanitchapoom
Prachaya Srivanitchapoom
YPYuvadee Pitakpatapee
Yuvadee Pitakpatapee
SLSomchai Leelakusolvong
Somchai Leelakusolvong
INTRODUCTION: Constipation, a prevalent nonmotor symptom in Parkinson disease (PD), adversely affects patients' quality of life. Prucalopride, a selective serotonin type 4 receptor agonist, has shown efficacy as a treatment of functional constipation, but its role in PD-related constipation remains underexplored. The objective of this study was to assess the efficacy, safety, and quality-of-life impact of prucalopride in PD patients with chronic constipation. METHODS: In this double-blind randomized controlled trial, PD patients with chronic constipation received prucalopride (2 mg) or placebo once daily for 8 weeks. The primary outcome was the change in the number of spontaneous bowel movements (SBMs) per week from baseline to week 8. Secondary outcomes included stool consistency, straining, and changes in Patient Assessment of Constipation-Symptoms and Patient Assessment of Constipation-Quality of Life scores. Parkinsonian motor severity was assessed using the Unified Parkinson Disease Rating Scale. RESULTS: Fifty-seven patients were included (prucalopride = 30, placebo = 27). At week 8, the change in the number of weekly SBMs was significantly larger in the prucalopride group (3.2 ± 2.8) than in the placebo group (1.6 ± 1.9; P = 0.02). Longitudinal analysis confirmed a significantly higher SBM frequency in the prucalopride group throughout the 8-week period ( P = 0.015). Secondary outcomes showed trends toward improvement but no statistically significant differences. No serious adverse events were reported, and Unified Parkinson Disease Rating Scale scores remained unchanged. DISCUSSION: Prucalopride was safe, well-tolerated, and more effective than placebo in increasing bowel movement frequency in PD patients with chronic constipation, supporting its potential as a therapeutic option in this population.

30 July 2024 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
TCTHANABOON CHAEMSUPAPHAN
THANABOON CHAEMSUPAPHAN
TGTanawat Geeratragool
Tanawat Geeratragool
NANapat Angkathunyakul
Napat Angkathunyakul
APArissa Phothisirisakulwong
Arissa Phothisirisakulwong
MMMonthira Maneerattanaporn
Monthira Maneerattanaporn

27 August 2026 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
TGTanawat Geeratragool
Tanawat Geeratragool
TATHANAPAT ATTHAKITMONGKOL
THANAPAT ATTHAKITMONGKOL
STSupathep Tansirichaiya
Supathep Tansirichaiya
PWPubet Weeranawin
Pubet Weeranawin
SLSomchai Leelakusolvong
Somchai Leelakusolvong
MMMonthira Maneerattanaporn
Monthira Maneerattanaporn
INTRODUCTION: Rapid urease test (RUT) is widely used for diagnosing Helicobacter pylori (HP) because it is inexpensive and practical. However, its accuracy is reduced in peptic ulcer bleeding (PUB). We prospectively performed a head-to-head comparison of diagnostic tests in the same patients to evaluate their performance in this setting. METHODS: After endoscopic hemostasis, gastric biopsies were obtained for RUT, histology, and polymerase chain reaction (PCR). Blood samples were collected for current infection marker and antiurease antibody. Urea breath testing (UBT) was performed in patients with negative RUT and histology. Diagnostic performance was assessed using a composite reference standard defined by at least 2 positive results among RUT, histology, PCR, and UBT. Logistic regression was used to identify factors associated with false-negative RUT. RESULTS: A total of 135 patients with PUB were enrolled, of whom 36 (26.7%) were HP-positive. Sensitivity/specificity was 69.4%/97.0% for RUT, 55.6%/96.0% for histology, 97.2%/92.9% for PCR, 77.8%/77.8% for current infection marker, and 83.3%/62.6% for antiurease antibody. Combining RUT, histology, and either PCR or UBT increased sensitivity to 100% and significantly outperformed RUT alone ( P = 0.021 and P = 0.001, respectively). PCR reduced idiopathic ulcers from 31.9% to 26.7%. Only 43 of 98 patients with negative RUT and histology underwent UBT because of clinical constraints, limiting its practicality despite excellent performance. No predictors of false-negative RUT were identified. DISCUSSION: In PUB, tissue PCR showed the best overall diagnostic performance among the single tests. RUT alone is insufficient for diagnosing HP, whereas combined testing with RUT, histology, and PCR or UBT achieved the highest diagnostic performance.